Mortality and recurrence patterns of breast cancer patients diagnosed under a screening programme versus comparable non-screened breast cancer patients from the same population: analytical survey from 2002 to 2012

Fernández, Antonia; Chabrera, Carolina; Font, Marc García; Fraile, Manuel; Lain, J. M.; González, Sónia; Corral, Christopher del; Torras, María de los Ángeles Calvo; Torres, Jennifer; Teixido, Michael; Barco, Israel; López, Rossana Mendoza; González, Clarisa; Pessarrodona, Antoni; Giménez, Núria

doi:10.1007/s13277-013-1260-7

Cited by 16 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As already discussed [26], in our experience, patients from the screening program have much better outcome than same-age patients outside the screening program.…”

Section: Discussionsupporting

confidence: 55%

Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…As already discussed [26], in our experience, patients from the screening program have much better outcome than same-age patients outside the screening program.…”

Section: Discussionsupporting

confidence: 55%

Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…The last two decades of cancer education have significantly improved screening rates with tools such as mammography [14]. Public service announcements (PSA) and health education programs that include celebrities, humorous expressions, and slogans have raised awareness of the importance of cancer screening [15, 16].…”

Section: Cancer Risk In the Orthodox Jewish Communitymentioning

confidence: 99%

Barriers to Cancer Screening Among Orthodox Jewish Women

et al. 2014

View full text Add to dashboard Cite

“…Different molecular subtypes of breast cancer not only have some common characteristics of malignant tumors, but also different biological features [4][5][6] . For example, the luminal A subtype of breast cancer has positive estrogen receptor (ER) and/or progesterone receptor (PR), a Ki67 < 20%, and negative human epidermal growth factor receptor (HER2) [7] , which is generally associated with a highly favorable prognosis [8] and typically exhibits less frequent and less extensive lymph node involvement [9][10] . The luminal A subtype of breast cancer also tends to have a more indolent course with a slower evolution over time when compared with the other molecular subtypes [11] .…”

Section: Introductionmentioning

confidence: 99%

Heterogeneity of luminal A and HER2-positive breast cancer based on DIA quantitative proteomics and bioinformatics analysis techniques

Wu¹,

Zhang²,

Liang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Breast cancer has common tumor biological characteristics, but different characteristics also exist among different subtypes. Different treatment strategies have been adopted for different subtypes at present, but there are still many problems. Thus, an-depth study on the heterogeneity of different types of breast cancer will help to identify new diagnostic therapeutic targets and solve the existing problems of individualized treatment for breast cancer.Methods: In this study proteins of HER2-positive breast cancer, luminal A breast cancer, and para-cancer tissues were quantified based on data independent acquisition (DIA) proteomics technology, and the differentially expressed proteins (DEPs) were screened and analyzed by IPA software and the database among the luminal A (LA ) versus para-cancer tissues (PT) and HER2 versus LA groups.Results: There were 264 up- and 123 down-regulated proteins in the LA versus PT groups. PD-1 and PD-L1 cancer immunotherapy pathways were significantly inhibited, and XBP1 was predicted to be the strongest activator. MTOR was predicted to be the strongest inhibitor. The DEPs were significantly associated with “Cancer” and “Organismal Injury and Abnormalities.” There were 134 up- and 286 down-regulated proteins in the HER2 versus LA groups. Signaling by rho family GTPases was significantly inhibited. XBP1 was predicted to be the strongest activator. TGFB1 was predicted to be the strongest inhibitor. The DEPs were significantly associated with “Cancer,” “Endocrine System Disorders,” and “Organismal Injury and Abnormalities.”Conclusion: Luminal A breast cancer may be insensitive to PD-1 and PD-L1 inhibitors. Signaling by rho family GTPases and RhoGDI signaling play a unique role in the proliferation and metastasis of luminal A and HER2-positive breast cancer, respectively. XBP1 is a promising new target for the treatment of breast cancer, and TGFB1 may play different biological roles in HER2-positive and luminal A breast cancer.

show abstract

Mortality and recurrence patterns of breast cancer patients diagnosed under a screening programme versus comparable non-screened breast cancer patients from the same population: analytical survey from 2002 to 2012

Cited by 16 publications

References 27 publications

Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification

Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification

Barriers to Cancer Screening Among Orthodox Jewish Women

Heterogeneity of luminal A and HER2-positive breast cancer based on DIA quantitative proteomics and bioinformatics analysis techniques

Contact Info

Product

Resources

About